Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus

Yaniv Sherer, Yehuda Shoenfeld

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Intravenous immunoglobulin (IVIg) is used for replacement therapy in immunodeficiency states and for immunomodulation of various autoimmune diseases. Several case reports and series support a beneficial role of IVIg in systemic lupus erythematosus (SLE), both as salvage immunotherapy and in control of disease activity in general and amelioration of classical disease manifestations. Further, lupus nephritis can also be treated usually successfully with IVIg. A few questions remain unanswered as to the appropriate therapeutic dosage and the clinical manifestations that can be best treated with IVIg.

Original languageEnglish
Pages (from-to)153-155
Number of pages3
JournalAutoimmunity Reviews
Issue number2 SPEC. ISS.
StatePublished - 1 Jan 2006
Externally publishedYes


  • Immunomodulation
  • Intravenous immunoglobulin
  • Systemic lupus erythematosus


Dive into the research topics of 'Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this